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Objectives: To evaluate the cost-effectiveness of denosumab (Prolia®, 60 mg every 
6 month) compared to generic zoledronic acid (5 mg once yearly) in the treatment 
of postmenopausal osteoporosis in the U.S. societal perspective. MethOds: 
Comprehensive literature and online search was employed to obtain data on the 
clinical effectiveness of drugs, health-related quality of life (HRQoL) of disease 
states and costs. Databases searched were PubMed and Google Scholar engine. A 
Markov cohort model was constructed within the framework of incremental cost 
effectiveness ratios (ICERs) and net monetary benefit analyses. Given that generic 
zoledronic acid dominates denosumab in the base-case scenario, only one-way 
sensitivity analyses were performed to evaluate the sensitivity of results to model 
parameters. Finally, threshold analyses were used to determine the price at which 
denosumab would be as cost-effective as generic zoledronic acid. Results: In the 
base-case scenario, generic zoledronic acid increased 0.003 QALYs and decreased 
$227 costs incrementally compared to denosumab. Assuming a willingness-to-pay 
threshold of $150,000 per QALY, the NMB value of generic zoledronic acid compared 
to denosumab was $679. In the one-way sensitivity analyses, generic zoledronic 
acid dominated denosumab in all scenarios when model parameters were var-
ied within a range of 10% -15%. The threshold analyses indicated that even at a 
zero price, denosumab would not be cost effective relative to generic zoledronic 
acid. cOnclusiOns: Based on a U.S. societal perspective, generic zoledronic acid 
is more cost-effective than denosumab in the treatment of high-risk patients with 
postmenopausal osteoporosis.
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Osteoarthritis (OA) is the most common joint disease in the Chilean population, 
and its treatment is guaranteed under a governmental program called “Explicit 
Health Guarantees” (GES). The chronic use of the drugs covered, non-steroidal 
anti-inflammatory (NSAIDs) and selective COX-2 inhibitors, is associated with 
gastrointestinal and cardiovascular complications. Objectives: To estimate the 
incremental cost-effectiveness ratio (ICER) of treating patients 65 years old (y/o) 
and older with Celecoxib compared to NSAIDs. MethOds: A cost-utility analysis 
was performed using a Markov model. Effectiveness data and likelihood of adverse 
events were extracted from CONDOR, MEDAL, CLASS and TARGET studies. Resource 
use was obtained from the recommendations of clinical guidelines. Unit costs were 
extracted from Chilean secondary databases or costs studies (September 2012). 
Target population: Patients 65+ y/o with mild to moderate OA. Perspective: Chilean 
public health system. Interventions: Acetaminophen, Diclofenac, Celecoxib, and 
association with proton pump inhibitor (PPI: Omeprazole). Time horizon: 6 months 
for base case. Outcome: incremental cost per quality-adjusted life year (QALY). Costs 
were measured in Chilean pesos, and converted to USD. Sensitivity analyses were 
performed, including treatment period (3-24 month), age (55-65 y/o), eliminating 
cardiovascular benefits, among others. Results: The gained QALYs for Diclofenac, 
Acetaminophen and Celecoxib were 0.31, 0.33 and 0.37 respectively (0.35, 0.34 and 
0.40 QALYs for Celecoxib+PPI). Considering the cost of care and complications, com-
pared to Acetaminophen, Celecoxib reported an ICER of USD 3497/QALY (USD 1780/
QALY for Celecoxib+PPI). Compared to Diclofenac+PPI, the ICERs for Celecoxib and 
Celecoxib+PPI were USD 8408/QALY and USD 2778/QALY. The ICERs decrease slightly 
if the time horizon increases to 1 or 3 years. All these ICERs were under the Chilean 
GDP per capita. cOnclusiOns: Using Celecoxib for OA is highly cost-effective com-
pared to other NSAIDs in the Chilean context, according to WHO recommendation, 
due to the lower incidence of complications.
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Objectives: In cost-effectiveness analysis, it is often necessary to characterize 
the incidence of events in patients with and without risk factors. Yet, the needed 
background incidence for patients without risk factors (incidence_no_risk) may be 
unavailable in the published literature. Previously, researchers have used the gen-
eral population incidence (incidence_pop), derived from epidemiological studies. 
However, when incidence_pop is used the model will overestimate the true inci-
dence because incidence_pop is a weighted average of the incidences in patients 
with and without risk factors. The purpose of this study was to develop a general 
method for deriving a true baseline risk (incidence_no_risk) using a downward 
adjustment of incidence_pop. This is illustrated with the condition of osteoporo-
sis. MethOds: In osteoporosis, the fracture incidence for high-risk persons (inci-
dence_risk) can be calculated by the patient’s baseline risk times the relative risk 
increase (RR_risk) due to risk factors (incidence_risk = incidence_no_risk*RR_risk). 
Published studies report RR_risk, incidence_pop, and the prevalence of the risk 
factor (p). The fracture incidence in the study population can be represented as 
follows: incidence_pop = incidence_risk*p + incidence_no_risk*(1-p). Therefore: 
incidence_pop = incidence_no_risk*RR_risk*p + incidence_no_risk*(1-p) incidence_
pop = incidence_no_risk*((RR_risk*p)+(1-p)) incidence_pop/((RR_risk*p)+(1-p)) = 
incidence_no_risk Results: The resulting equation is: incidence_no_risk = inci-
dence_pop/((RR_risk*p)+(1-p)). We tested incidence_pop as the baseline fracture 
incidence in an osteoporosis model, which had consistently overestimated the true 
MarketScan® Commercial Database from January 2009-July 2013. The patient’s 
first biologic claim (index claim) defined their treatment cohort. Patients were 
required to have continuous enrollment 6-months prior and 24-months follow-
ing their index claim and have a pre-index RA diagnosis. Patients with pre-index 
biologic use (including ustekinumab) or a diagnosis for other conditions that the 
study biologics are approved for were excluded. Effectiveness was estimated using 
a validated, published claims-based algorithm. Medications were considered effec-
tive until any of the following criteria were met; biologic dose escalation, switching 
biologics, adding a new non-biologic RA medication, receiving > 1 intra-articular 
injection, adding a glucocorticoid, increasing glucocorticoid dose, or low treatment 
compliance (< 80%). Each failure event had a 90-day non-response period and 
patients could experience multiple failure events over the follow-up. Costs were 
the sum of RA-related medical, pharmacy, and drug administration costs post-index 
and were attributed based on the index biologic. Cost per patient-year in response 
was defined as RA-related costs divided by the time in response. Results: 8,193 
patients (mean age = 49, 78% female) met the selection criteria. Cost per year in 
response was lower for etanercept ($26,610) compared with abatacept ($40,457, 
p< 0.001), adalimumab ($28,031, p= 0.003), golimumab ($28,722, p= 0.030), and inf-
liximab ($40,507, p< 0.001). Certolizumab also had numerically higher cost per 
patient-year in response ($28,486) compared to etanercept; however, this was not 
statistically significant (p= 0.141), possibly due to a smaller sample size for certoli-
zumab (n= 184). cOnclusiOns: Using this algorithm, etanercept was estimated as 
the most cost-effective RA biologic with the lowest cost per patient-year in response 
among FDA-approved biologics for RA.
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Objectives: Rheumatoid Arthritis (RA) affects approximately 0.4% of the Latin 
American population over 16 years of age. [1] Decreased pain and disability pre-
vention may be possible with a early diagnosis and appropriate treatment. [2] The 
objective is to assess the cost-effectiveness (CE) of Etanercept in the treatment for 
moderate to severe RA, with previous antirheumatic drugs failure, in comparison 
with the rest of anti-TNF and IL-6 blockers available in Dominican Republic, from the 
health care payer’s perspective. MethOds: A decision tree model was implemented 
to compare the costs and effectiveness of Etanercept (comparator, 25mg/ 2 times 
per week), Adalimumab (40mg/every two weeks), Infliximab (3 mg/kg at 0, 2 and 
6 weeks, then every 8 weeks), Rituximab (1000mg day 0 and 15, with reevaluation 
every 24 weeks) and Tocilizumab (8mg/kg every 4 weeks), all in combination with 
Methotrexate. The effectiveness measures were: American College of Rheumatology 
(ACR) Response Criteria ACR20 and ACR70. Quality utilities were obtained from 
Health Assessment Questionnaire (HAQ). Local costs (2013 US$) were obtained from 
Local Public Health databases. The outcomes were: total costs of RA (adverse events, 
exams and treatments) and QALYs gained. Probabilistic sensitivity analysis was 
performed. The time horizon was 2 years and the discount rate was 5% for costs 
and health outcomes. Results: The total cost of Etanercept was $US30,355.46, 
being $US1,968.70, $US175.92, $US3,930.32, and $US11,260.72 less expensive than 
Adalimumab, Infliximab, Tocilizumab and Rituximab respectively. Etanercept also 
gained the highest number of QALYs (1.5423) in comparison with adalimumab 
(1.5048), infliximab, (1.4299), tocilizumab (1.4955) and rituximab (1.4674). Cost-
effectiveness analyses showed Etanercept as the dominant strategy. Acceptability 
curves showed that at the willingness-to-pay of US$17200/QALY, the probability that 
etanercept is cost-effective met 100%. [3] cOnclusiOns: Etanercept appeared as 
the most cost-effective alternative for RA against other anti-TNF and IL-6 blockers 
in Dominican Republic.
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Objectives: Using rituximab for patients with rheumatoid arthritis who are 
refractory to conventional and/or biologic “disease modifying anti-rheumatic 
drugs” (DMARDs) is common choice of therapy in Iran. We evaluated the effec-
tiveness and cost-effectiveness of using rituximab for these patients in compari-
son to continuing conventional DMARDs, from a perspective of health service 
governors. MethOds: A systematic review was implemented through search-
ing MEDLINE, Scopus and Cochrane Library. Inclusion criteria were being an RCT 
on rituximab, for refractory rheumatoid arthritis patients, and with a control 
group of DMARDs. Included articles were qualified by JADAD questionnaire. Risk 
Difference and CI95 were calculated and heterogeneity was tested by the Cochran 
Q test. To measure the direct and indirect medical costs, a set of interviews with 
patients were applied. Thirty two patients were selected from three referral clin-
ics in Tehran with definite diagnosis of refractory rheumatoid arthritis in the 
year before, and treatment regimen of either rituximab or DMARDs within last 
year. Incremental cost-effectiveness ratio was calculated using mean of costs 
for 6 months period and risk difference, with a scenario and sensitivity analy-
sis. Results: From 1875 related articles, 4 studies were eligible to be considered 
in this systematic review. Results of meta-analysis showed homogeneity of all 4 
studies and a total risk difference of 0.3 for ACR20 criteria, 0.2 for ACR70WR, and 
0.37 for EULAR criteria of response. Also mean of total medical costs of patients 
for one year were $7957 in rituximab group and $1861 for DMARDs group. Hence, 
the cost-effectiveness ratio will be $10159 per ACR20, $15238 per ACR70WR, and 
$8237 per EULAR in base case analysis, while in generic rituximab scenario shows 
a 30% reduction of results. cOnclusiOns: Rituximab for patients with refractory 
rheumatoid arthritis does not seem to be cost-effective in Iran, although generic 
use of this drug can be encouraged.
